Exenatide (exendin-4) is sold under the brand name BYETTA to improve glycemic control in people with type 2 diabetes mellitus. Exenatide is a glucagon-like peptide 1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion by the pancreatic beta cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying. The drug also moderates peak serum glucagon levels during hyperglycemic periods following meals but does not interfere with glucagon release in response to hypoglycemia.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12629557
Curator's Comment: Referenced study was conducted in mice
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P43220 Gene ID: 2740.0 Gene Symbol: GLP1R Target Organism: Homo sapiens (Human) |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | BYETTA Approved UseBYETTA (exenatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Launch Date2005 |
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000170335
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
||
|
WHO-ATC |
A10BJ01
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/16/1629
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
||
|
WHO-ATC |
A10BX04
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
||
|
WHO-VATC |
QA10BX04
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
||
|
FDA ORPHAN DRUG |
530516
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
||
|
NDF-RT |
N0000178480
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
||
|
NDF-RT |
N0000020058
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
||
|
LIVERTOX |
NBK548665
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
EXENATIDE
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
PRIMARY | |||
|
60548
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID9040475
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
PRIMARY | |||
|
C074031
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
PRIMARY | |||
|
100000089569
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
PRIMARY | |||
|
1123
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
PRIMARY | |||
|
141758-74-9
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
PRIMARY | |||
|
C65611
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
PRIMARY | |||
|
Exenatide
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
PRIMARY | |||
|
8219
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
PRIMARY | |||
|
1135
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
PRIMARY | |||
|
64073
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
PRIMARY | |||
|
CHEMBL414357
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
PRIMARY | |||
|
9P1872D4OL
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
PRIMARY | |||
|
SUB21818
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
PRIMARY | |||
|
141732-76-5
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
SUPERSEDED | |||
|
m5225
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
PRIMARY | |||
|
7789
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
PRIMARY | |||
|
NN-05
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
PRIMARY | |||
|
DB01276
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
PRIMARY | |||
|
9P1872D4OL
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
PRIMARY | |||
|
1269105
Created by
admin on Sat Dec 16 18:35:38 GMT 2023 , Edited by admin on Sat Dec 16 18:35:38 GMT 2023
|
PRIMARY |
ACTIVE MOIETY